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Abstract
Barrett’s esophagus (BE) epithelium is the precursor
lesion for esophageal adenocarcinoma. Cell cycle
proteins have been advocated as biomarkers to predict
the malignant potential in BE. However, whether dis-
ruption of the cell cycle plays a causal role in Barrett’s
carcinogenesis is not clear. Specimens from the
Barrett’s dysplasia–carcinoma sequence were immu-
nostained for cell cycle phase markers (cyclin D1 for
G1; cyclin A for S, G2, and M; cytoplasmic cyclin B1 for
G2; and phosphorylated histone 3 for M phase) and
expressed as a proportion of proliferating cells. Flow
cytometric analysis of the cell cycle phase of pro-
spective biopsies was also performed. The prolifer-
ation status of nondysplastic BE was similar to gastric
antrum and D2, but the proliferative compartment
extended to the luminal surface. In dysplastic samples,
the number of proliferating cells correlated with the
degree of dysplasia (P < .001). The overall levels of
cyclins A and B1 correlated with the degree of dys-
plasia (P < .001). However, the cell cycle phase distri-
bution measured with both immunostaining and flow
cytometry was conserved during all stages of BE,
dysplasia, and cancer. Hence, the increased prolifer-
ation seen in Barrett’s carcinogenesis is due to abnor-
mal cell cycle entry or exit, rather than a primary
abnormality within the cell cycle.
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Background
Cancer is characterized by the loss of proliferative and
apoptotic control, leading to a growth advantage of malig-
nant cells compared to their nonmalignant counterparts.
These abnormalities in growth control mechanisms accu-
mulate gradually because most epithelial malignancies
have a premalignant stage that may progress to cancer
over a period of years [1]. Barrett’s esophagus (BE) is a
premalignant, metaplastic condition in which the normal
squamous epithelium lining the esophagus is replaced by
a glandular epithelium akin to that found in gastric and
intestinal mucosa. Esophageal adenocarcinoma (AC) grad-
ually develops from BE through a dysplasia–carcinoma se-
quence in an estimated 5% to 10% of patients [2,3]. The
grading of dysplastic changes within BE by histopathologic
criteria is highly subjective [4], and we are very limited in our
ability to predict the point at which progression to AC is
inevitable. To develop prognostic tests and curative interven-
tion strategies for patients with BE, it is necessary to under-
stand the stage at which normal growth controls are abrogated
and the molecular mechanisms that are involved.
In the quest for predictive markers of progression to cancer,
cell cycle stage and cell cycle–related proteins have been
investigated in BE over the last 20 years. Several retrospective
studies using flow cytometry demonstrated that the number of
cells in gap 1 (G1), DNA synthesis (S), gap 2 (G2), and mitosis
(M) phases increased with progression from BE to AC [5,6].
In addition, a prospective study linked increased G2/tetraploid
phases fraction with progression from nondysplastic and dys-
plastic BE to AC [7–10]. Apart from these flow cytometry
studies, most of the works done on cell cycle–related mole-
cules in BE have been performed by immunohistochemistry
because paraffin-embedded tissue is readily available and
permits the determination of the distribution of these markers.
Overexpression of cyclin D1, expressed in mid- to late-G1 [11],
has been shown to have a predictive value for progression to
neoplasia in a retrospective, longitudinal, case–control study
[12]. The increased expression of cyclins E and B1 along the
progression from BE to AC has been suggested to result from
an increased entry into S [13] and G2/M phases, respectively
[14]. Hence, all of these studies led to the conclusion that there
is an overexpression of cell cycle proteins, or deregulation of
cell cycle phase distribution as BE progresses toward AC.
These studies were generally conducted with the aim of
identifying a predictive marker for cancer progression and, in
most cases, the study was restricted to a single protein marker.
By studying an individual cell cycle marker independently of
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the proliferation status, it is not possible to determine whether
the findings are due to overexpression of a specific protein, or
are a consequence of the overall increase in proliferation.
Recently, with an increased understanding of the key
regulators of cell cycle progression and proliferation, cell
cycle markers with a greater specificity have become avail-
able [15]. Minichromosome maintenance (MCM) proteins
are expressed in all cells in a cycle [16,17], whereas the
timing of expression of Ki-67 in cycling cells is subject to
controversy [18]. Cyclins, proteins involved in the tight reg-
ulation of cell cycle progression, are markers of choice as
they are expressed at specific phases of the cell cycle. Cyclin
D1 is expressed in mid- to late-G1 phase, and is translo-
cated to the cytoplasm in S phase where it is degraded [11].
Cyclin A is expressed in early S phase and is degraded
during metaphase [19]. Cyclin B1 accumulates in the cyto-
plasm of cells in the G2 phase, and is then translocated to the
nucleus in early mitosis to be degraded at the metaphase–
anaphase transition [20,21]. Histone H3, one of the four
histones composing the nucleosome, is phosphorylated in
late G2 to early M to allow chromosome condensation [22].
The phosphorylation levels peak during metaphase and
start to decrease in anaphase, and histone H3 is dephos-
phorylated during telophase before chromosomes decon-
dense [23]. The use of those molecules as cell cycle markers
has been previously validated in the context of colorectal
neoplasia [15].
The aim of this study was to perform a comprehensive
analysis of the overall proliferation status and cell cycle stage
distribution in BE-associated carcinogenesis. We demon-
strate that although cell proliferation increases during the
progression to BE dysplasia and cancer with a disordered
proliferation compartment, the distribution of the cell cycle
phases is conserved.
Methods
Patients and Tissue Collection
Samples for immunostaining Archival blocks were ob-
tained from patients who had attended Addenbrooke’s Hos-
pital (Cambridge, UK) and Middlesex Hospital (London, UK).
We studied 35 cases of nondysplastic BE, 26 low-grade
dysplasia (LGD), 11 high-grade dysplasia (HGD), and 16
invasive AC from different patients. Sections of nonmalig-
nant, normal tissues from BE and non-BE patients were used
as control specimens [10 from the second part of the
duodenum (D2) and 20 from the gastric antrum].
Samples for flow cytometry Two biopsies per patient
(6 D2, 4 gastric, 13 BE, 8 LGD, and 6 AC) were placed in
Dulbecco’s modified Eagle’s medium (Invitrogen, Paisley,
UK) containing 10% fetal calf serum and 10% dimethyl
sulfoxide (Sigma, Gillingham, UK) at the time of endoscopy.
Samples were transported on ice, then stored at 80jc until
processed. D2 and gastric antrum control samples were
taken from patients with no endoscopic or histopathologic
abnormality in these anatomic areas. Biopsies were called
LGD only if patients had multifocal LGD throughout the BE
segment to avoid sample bias.
AllpatientswithBEhadanendoscopicallyvisiblecolumnar-
lined segment and a histopathologic diagnosis of specialized
intestinal metaplasia. Approval for this study was obtained
from the Local Research Ethics Committees.
Immunostaining
Specificity of all the antibodies was confirmed by Western
blot analysis (data not shown). For all antibodies except
cyclin D1, tissue sections were deparaffinized in xylene
and rehydrated through alcohol solutions, water, and, finally,
Tris-buffered saline–Tween (1.4 mol/l NaCl, 0.25 mol/l Tris–
base, and 0.025% Tween; TBS–Tween). Washes using
TBS–Tween were performed between each step. An anti-
gen retrieval step was performed by pressure-cooking
samples for 3 minutes in 0.01 M Tris–sodium citrate buffer
at pH 6.0. Staining was performed using the Dako auto-
stainer Dako ChemMale (DakoCytomation Ltd., Ely, UK) and
the staining kit Dako ChemMate for increased reproducibil-
ity. Blocking of nonspecific binding was performed using 10%
normal goat serum and 10% bovine serum albumin for 30
minutes at room temperature. The samples were incubated
for 1 hour at room temperature with each of the following
antibodies diluted in antibody diluent (DakoCytomation Ltd.):
monoclonal Mcm2 antibody (dilution 1/10; gift from Steve
DilworthandRonLaskey),anti–Ki-67antibody(dilution1/100,
MIB-1; DakoCytomation Ltd.), anti–cyclin A antibody (dilu-
tion 1/20; Novocastra, Newcastle upon Tyne, UK), anti–
cyclin B1 antibody (dilution 1/400; DakoCytomation Ltd.),
anti–phosphorylated histone H3 (pH3) antibody (dilution 1/
300; Upstate Biotechnology, Buckingham, UK). Endogenous
peroxidase activity was blocked with peroxidase blocking
solution (DakoCytomation Ltd.) for 5 minutes. The secondary
and peroxidase-linked antibody were both incubated subse-
quently for 30 minutes at room temperature followed by DAB
substrate (DakoCytomation Ltd.) for 10 minutes. Sections
were counterstained with hematoxylin. A negative control
was performed by omission of the primary antibody.
Cyclin D1 antibody (dilution 1/50; DakoCytomation Ltd.)
staining was performed by hand using Dako Target Retrieval
Solution High pH (DakoCytomation Ltd.) to perform the anti-
gen retrieval step in a microwave for 30 minutes at 98jC.
The staining procedure was performed using the Dako
EnVisionTM + System. This kit replaces the peroxidase block
and the secondary and peroxidase-linked antibody with a
peroxidase-labeled polymer applied for 30 minutes. The
DAB solution was then added for 10 minutes. Washing steps
were performed between each step with TBS–Tween.
Validation of Cyclin A Expression in the Context of BE
It is generally accepted that cyclin A is expressed in S and
G2/M phases [19]; however, it has been demonstrated
that for colorectal cancer, immunohistochemical expression
of cyclin A might only be detectable in S phase [15]. To test
this in the context of BE, we performed colocalization studies
between cyclin A and pH3. A fraction of epithelial cells
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staining for both cyclin A and pH3 was seen in BE mucosa
(Figure 1), suggesting that cyclin A is indeed present in G2/M
phases and that cyclin A is a marker of S–G2 and M.
Scoring Immunohistochemistry
For glandular epithelia, the mucosal compartment of each
well-oriented section was divided into the following three
zones: 1) luminal surface (the most superficial layer of the
columnar epithelium); 2) upper crypt (upper half of the crypt);
and 3) proliferative compartment (lower half of the crypt and
underlying glands) [24]. The upper and lower crypts were
divided halfway between the surface and the bottom of the
crypt. The number of immunopositive epithelial cells was
calculated as a percentage of the total number of epithelial
cells. The percentage of proliferative cells positive for each
marker refers to the percentage of cells positive for a given
marker divided by the percentage of cells positive for one of
the proliferation markers from the same biopsy sample
(either Mcm2 or Ki-67) multiplied by 100. The whole surface,
and as many well-oriented crypts and glands as possible,
were counted. Twenty-five percent of the sections stained for
Mcm2 and Ki-67 were also analyzed by an independent
pathologist (R.B.).
Flow Cytometry
Biopsies were processed for cell cycle analysis by flow
cytometry using a modification of the technique described by
Reid et al. [6]. Briefly, biopsies were minced in NST buffer
(146 mM NaCl, 10 mM Tris base, 1 mM CaCl2, 0.5 mM
MgSO4, 21 mM MgCl2, 0.05% bovine serum albumin, and
0.2% IGEPAL CA-630; Sigma) using a scalpel blade and
passed several times through a 25-gauge needle to break up
clumps. Samples were spun down and resuspended in NST
buffer containing 10% normal goat serum (DakoCytomation
Ltd.) and DAPI at 10 mg/ml. Each sample was separated into
two tubes to which were added anti–Ki-67–RPE (positive
sample; DakoCytomation Ltd.) at a dilution of 1/20 and
mouse IgG1–RPE (negative control; DakoCytomation Ltd.)
at a dilution of 1/25. Samples were then incubated for 1 hour
at 4jC. SEG-1 cells were used as a positive control. The
samples were spun down, resuspended in NST containing
DAPI (10 mg/ml), and passed through a 70-mm cell strainer
before being captured for cell cycle distribution on the flow
cytometer BE LSR2 (BD Biosciences, Oxford, UK) using a
FACSDIVA software and analyzed using ModFit (Verity
Software House, Topsham, ME). Previous data by Reid
et al. showed that although proliferating inflammatory cells
were present in the lamina propria, the proliferating cells
detected using Ki-67 immunostaining were predominantly
epithelial and, hence, microdissection of the specimen was
not deemed necessary [6].
Statistical Analysis
The paired Kruskal-Wallis test was used to identify differ-
ences between the two observers for the scores from Mcm2
and Ki-67 from. The Jonckheere-Terpstra test [25] and the
chi-square analysis for trend were used to assess the
correlation between the expression of individual markers
and the degree of dysplasia. The Jonckheere-Terpstra test
is a nonparametric statistic test used to identify a shift in
ordered distributions (Mcm2 surface expression) when strat-
ified by ordered categories (BE, LGD, HGD, and AC). The
Kruskal-Wallis test was used to identify specific differences
within a population, and the Mann-Whitney test was used
to identify specific differences between groups. In all cases,
P < .05 was required for significance to identify specific
differences [26].
Results
Proliferative Status of BE
The overall proliferation status of nondysplastic BE was
similar to that of gastric antrum and D2 for both Mcm2
(29.9 ± 2.5%, 25.2 ± 2.5%, and 34.7 ± 1.6%, respectively)
and Ki-67 (34.7 ± 2.1%, 23.9 ± 2.6%, and 32.8 ± 2.6%)
antibodies (Figure 2A) (P = ns between groups). Overall,
41% (gastric antrum) and 67% (duodenum) of the cells within
the proliferative compartment are Ki-67–positive and Mcm2-
positive (Figure 2B). Over 75% of these proliferating cells in
the gastric antrum and duodenum are confined to the prolif-
erative compartment (Figures 2B and 3). In contrast, in BE
samples, 40% of the proliferative cells were found in the
upper crypt and at the luminal surface even prior to the devel-
opment of dysplasia (Figures 2B and 3). This suggests that
outside of the normal proliferative compartment, differentiat-
ing cells re-enter the cell cycle, or cells do not differentiate
as they migrate toward the lumen.
Figure 1. Verification of expression of cyclin in BE mucosa. Colocalization of cyclin A (green), pH3 (red), and DNA (blue) in Barrett’s mucosa. The last panel
represents merging of the three pictures.
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The total number of proliferative cells in the epithelial
mucosa increased as BE progressed to AC (Figures 2A
and 3). Furthermore, the proliferation levels as judged by
Mcm2 and Ki-67 staining correlated with the grade of dys-
plasia (P < .0001 in both cases). As BE progresses to LGD
and, subsequently, to HGD, the percentage of proliferating
cells increases equally in each compartment (Figure 2B),
suggesting again an abnormal cell cycle entry/exit or a
decrease of cell cycle length. The levels of Mcm2 staining
were generally higher than Ki-67 staining for each tissue with
the exception of BE, where there were wide confidence
intervals for Mcm2 staining (Figure 2B).
Cell Cycle Distribution
Immunohistochemistry The cell cycle markers (cyclins D1,
A, and B1, and pH3) were expressed almost exclusively in
the proliferative compartment of the gastric antrum and D2
similar to Mcm2 and Ki-67 (Figure 4). Cyclin D1 staining was
absent from the epithelial cells and intramucosal lympho-
cytes of the D2 by immunostaining, but present in small
amounts by immunoblotting (Figure 4; data not shown),
suggesting that the antibody is unable to detect low levels
of cyclin D1 by immunohistochemistry. In all stages of BE car-
cinogenesis, the expression of cell cycle markers extended
to the luminal surface to an extent depending on the degree
of dysplasia (Figure 4), similar to the findings for Mcm2 and
Ki-67 (Figure 2B).
When expressed as a percentage of total epithelial cells,
the overall expression of cyclins A and B1 correlated with the
degree of dysplasia (12.9 ± 1.8% and 3.5 ± 0.4% in BE, 18.3
± 1.7% and 6.9 ± 0.8% in LGD, 23.1 ± 2.3% and 9.1 ± 1.7 in
HGD, and 29.9 ± 3.4% and 9.6 ± 1.4% in AC, respectively,
for cyclins A and B1, P < .001). The levels of pH3 increased
moderately as the tissue progressed to AC, but no statistical
significance was reached. No specific trend was seen with
regards to the expression of cyclin D1 (Figure 5A). In
contrast, when expressed as a percentage of the proliferat-
ing cells (i.e., those staining positive for Mcm2 or Ki-67),
cyclins D1, A, and B1 levels remain consistent as the tissue
progresses from BE to AC (Figure 5B). It was observed that
there was a statistically significant difference in the level of
cyclin B1 in BE when expressed as a percentage of Mcm2
compared with Ki-67 (Figure 5B) (P < .005). pH3 levels also
remained consistent along the progression from BE to AC
when expressed as a proportion of Ki-67–positive cells
(Figure 5B). However, the level of pH3 as a percentage of
Mcm2 staining is statistically significant between BE and AC
(P < .03). These statistical differences for pH3 and cyclin B1
may reflect the lower expression level of Mcm2 compared
to Ki-67 expression in BE (Figure 1B). However, taken
together, the data for Mcm2 and Ki-67 suggest that for a
given level of proliferation, the cell cycle distribution is
conserved as BE progresses to AC.
Flow cytometry Flow cytometric analysis of cell cycle
phase using endoscopic biopsies was then performed to
confirm the results obtained by immunohistochemistry.
Figure 6A demonstrates the results when nuclei were incu-
bated with mouse IgG1–RPE (negative control) to set the
limit between Ki-67–RPE–positive (above black line) and Ki-
67–RPE–negative nuclei (below, black line) (Figure 6A).
The cell cycle profile of Ki-67–positive cells (Figure 6C)
was derived from the results shown in Figure 6B. An aneu-
ploid population at 6N chromosomes was found in 66.7%
(4/6) of AC (Figure 6D). Interestingly, there was a statistically
significant increase of 7% in the G2/tetraploid phase of the
Ki-67–positive cells in AC when compared to the other
mucosa (P < .02) (Figure 6E ). The cells from this increased
G2/tetraploid fraction possibly represent the G1 fraction of
the aneuploid population found in AC. Cumulative data from
cell cycle profiling demonstrated that the percentage of cells
positive for Ki-67 in G1 and S phases was conserved in D2,
Figure 2. Cumulative data for proliferation indices and epithelial compartments in the upper gastrointestinal mucosa. Mcm2 and Ki-67 expression is shown as a
percentage of total epithelial cells (panel A) and according to the localization of proliferating cells (panel B) in the second part of the duodenum (D2), gastric antrum
(gastric), BE, LGD, HGD, and AC.
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gastric, BE, LGD, and AC, consistent with immunostaining
(no statistical significance in any case; Figure 6E ).
Discussion
In this study, we have demonstrated that the overall
proliferative index of nondysplastic BE is not increased
when compared to other glandular gastrointestinal mucosa.
Nevertheless, nondysplastic BE cannot be considered as a
normal mucosa because there are proliferating cells pres-
ent in the upper crypt and luminal surface of this epithe-
lium. These cells may have retained their proliferative
status as they migrated toward the region of the crypt
normally occupied by differentiated cells. There is an
overall increase in the number of proliferating cells ob-
served as BE progresses to LGD, HGD, and AC, as
expected. However, using two techniques, we have shown
that the cell cycle phase distribution is conserved through-
out the progression from nondysplastic BE to LGD, HGD,
and AC.
To assess the degree of cell proliferation, both Mcm2 and
Ki-67 were used (Figures 2 and 3). Ki-67 is a well-known
Figure 3. Expression of Mcm2 (brown immunostain, with blue hematoxylin counterstain) in representative tissue sections from the second part of the duodenum
(D2), gastric antrum (gastric), BE, LGD, HGD, and AC.
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proliferation marker [27], although its precise role is not
understood. In contrast, Mcm2 is known to be part of a
heteromeric–hexameric complex that binds to the origins of
replication to ensure a single round of DNA replication. Unlike
Ki-67, MCMs are expressed in all cycling cells throughout
the cell cycle and are degraded when mammalian cells exit
Figure 4. Immunohistochemical staining for cyclins D1, A, and B1, and pH3 in a representative tissue section from the gastric antrum (gastric), second part of the
duodenum (D2), BE, LGD, HGD, and AC.
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Figure 5. Expression of the cell cycle markers (cyclins D1, A, and cyclin B1, and pH3) in the gastric antrum (gastric), second part of the duodenum (D2), BE, LGD,
HGD, and AC. Panel A shows data as a percentage of total cells. Panel B shows data as a percentage of the proliferative fraction. The percentage of the
proliferative fraction was calculated by dividing the percentage of expression of each marker in a given sample by the percentage of proliferating cells (either Mcm2
or Ki-67) in the same slide. *P < .03; **P < .005.
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the cell cycle into quiescent, differentiated, and senescent
states [16,17,28]. This expression profile increases the sen-
sitivity of MCM antibodies to detect cycling cells; therefore,
MCM proteins have been proposed as candidate markers for
cancer screening and surveillance, and as prognostic
markers [29–34].
Figure 6. Flow cytometry results for upper gastrointestinal biopsy samples. Panels A–C are representative examples of analysis from a BE biopsy where 2N refers
to diploid cells (G0/G1 phase of the cell cycle) and 4N refers to tetraploid cells (G2/M cells). The black line in the negative control (panel A) represents the maximum
RPE intensity of unstained cells. In the positive samples (panel B), Ki-67–negative cells (G0) are below the line and Ki-67–positive cells are above. Ki-67–positive
nuclei only are used for the cell cycle profile (panel C). The rough black line represents raw data. The black areas at 2N and 4N denote cells in G1 and G2/M,
respectively, and the hashed area is the S phase. The components were fitted using ModFit. The cell cycle profile of a cancer sample exhibiting a tetraploid
population is shown for comparison (panel D). The 2N and 4N peaks only were used to obtain the cell cycle fractions. Panel E shows the cumulative data, which
demonstrated that the percentages of cells in G1 and S phases are similar for all tissue samples (D2, gastric antrum, BE, LGD, and AC). The percentage of Ki-67
cells in the G2/tetraploid phase is statistically increased in AC when compared to BE and LGD (*P < .02).
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In the published literature, the proliferative status of BE is
controversial. Two independent studies have demonstrated
that BE proliferates more than squamous epithelium [35,36],
but Iftikhar et al. [37] concluded on the contrary. We did not
compare the proliferative indices of BE with squamous
esophageal mucosa because their different architectures
make direct comparisons impossible. In previous studies,
which have compared the proliferative index of BE with other
glandular tissues, the results are conflicting. Studies using
tritiated thymidine incorporation reported similar indices be-
tween BE, gastric mucosa, and duodenum [36,38]; whereas
increased proliferation has been reported for BE compared
with gastric tissue by immunohistochemical analysis of Ki-67
[24]. These discrepancies may be due to the different
techniques used and the subjective interpretation of immu-
nostaining. It is possible that the proliferative status of non-
dysplastic BE reflects the change to a metaplastic, glandular
phenotype. However, in keeping with our data, there is
general agreement in the literature that the overall prolifer-
ative index increases as BE progresses to AC [6,24,39,40],
with an expansion of the proliferative compartment toward
the luminal surface [24,34,39,40].
The shift of the proliferative compartment, usually con-
fined to the lower crypt and glands, to the upper crypt and the
luminal surface has critical implications because we have
demonstrated previously that surface proliferation was of
prognostic value for the development of AC [34]. Overstim-
ulation of proliferation by growth factors, luminal factors, and
mutations in oncogenes [41] would be expected to increase
proliferation. TheWnt pathway is a tight regulator of crypt cell
fate and patterning in the intestinal mucosa [42] . Knockout
mice models of members of the Wnt pathway, Fkh6 (fork-
head homologue transcription factor) [43], and Nkx2-3 (NK 2
homeobox transcription factor) [44] can result in hyperproli-
ferative, expanded crypt compartments. It is therefore pos-
sible that these pathways are disrupted early in BE.
Most cancer cells have impaired cell cycle checkpoints,
resulting in the accumulation of genetic aberrations [45].
Studies of cell cycle molecules in BE have suggested an
array of abnormalities, but the work was not performed in the
context of overall proliferation status. If there is an increase in
cell proliferation, then more cells will be entering the cell
cycle (increased G1 fraction and cyclin D1 expression). Most
of the cells in G1 will progress into S phase (increased S
phase fraction) and then enter G2 (G2 accumulation and
cyclin B1 increased expression). Unless these cell cycle
markers are expressed as a fraction of the denominator
(proliferation), then there will be an apparent disruption of
cell cycle control. Our data suggest that the cell cycle phase
distribution is conserved throughout Barrett’s metaplasia–
dysplasia sequence.
In addition, the flow cytometry analysis demonstrated an
apparent increase in the G2/tetraploid fraction in AC (Figure
6, D and E) and an aneuploidy 6N peak in 66.7% of the AC
patients. It is therefore possible that the cells from the G2/
tetraploid fraction are tetraploid cells in G1, as flow cytometry
does not allow discriminating between tetraploid G1 cells and
true G2/M cells. A 7% increase in the cyclin D1 fraction
should have been observed, but the variability of the cyclin
D1 staining makes this difficult to deduce. A more sensitive
technique to measure the G1 fraction is required to resolve
this question. Furthermore, four patients in our study had an
increased G2/tetraploid content early in the metaplasia–
dysplasia sequence [2/13 BE (15%), and 2/8 LGD (20%)].
This finding is in keeping with previous data, which also
suggest that G2/tetraploidy status was of prognostic value
[7–10]. However, the sample size and cross-sectional na-
ture of our study mean that the prognostic significance of
these findings cannot be established.
Despite our findings that the cell cycle phase distribution
is conserved during carcinogenesis, proliferation and cell
cycle proteins may still be useful prognostic markers by
virtue that their overall expression level increases coinciden-
tally with the increased proliferation index. Both cyclin D1
and Mcm2 have proven valuable in a phase 3 longitudinal
case–control study design [12,34]. In our hands, despite the
use of different cyclin D1 antibodies, the results were found
to be heterogeneous both within and between the different
tissues examined. These practical difficulties would limit its
application to clinical practice. Phases 3 and 4 prospective
studies are required to accurately determine the clinical utility
of any of these molecular markers [46].
In conclusion, we have demonstrated that there is no
primary abnormality in the cell cycle stage that could account
for the increased and disordered cell proliferation during the
Barrett’s metaplasia–dysplasia sequence. This suggests
that abnormal cell cycle entry or exit and possibly a short-
ened cell cycle length may be responsible for the increased
proliferative index. A better understanding of the molecular
mechanisms controlling cell cycle entry may pave the way for
clinically valid prognostic markers and novel therapeutic
targets.
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